Delcath SystemsDCTH -0.41%70 EBITDA Margin % is -6.03% as of Mar. 2026. GuruFocus rates DCTH with a GF Score™ of 70/100 and a GF Value™ of $36.67 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Delcath Systems ranks worse than 62.01% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Delcath Systems's EBITDA for the
three
months ended in Mar. 2026 was $-1.51 Mil. Delcath Systems's Revenue for the
three
months ended in Mar. 2026 was $24.99 Mil. Therefore, Delcath Systems's EBITDA margin for the quarter that ended in Mar. 2026 was -6.03%.
Delcath Systems (NAS:DCTH) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Delcath Systems EBITDA Margin % Related Terms
Delcath Systems EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Delcath Systems's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DCTH vs OFIX, VMD, CLPT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Delcath Systems's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Delcath Systems EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Delcath Systems's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Delcath Systems's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Delcath Systems (DCTH) has a EBITDA Margin % of -6.03% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Delcath Systems and its competitors. According to the industry distribution chart, Delcath Systems ranks #506 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 62%.
Is Delcath Systems' EBITDA Margin % too high?
Delcath Systems' current EBITDA Margin % is -6.03%. Based on the distribution chart, Delcath Systems ranks #506 out of 816 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Delcath Systems has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Delcath Systems' EBITDA Margin % compare to OFIX and VMD?
According to the Medical Devices & Instruments industry distribution chart, Delcath Systems ranks #506 out of 816 companies for EBITDA Margin %. This places Delcath Systems in the lower half of its industry. The industry median EBITDA Margin % is 7.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Delcath Systems and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Delcath Systems's current EBITDA Margin % is -6.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Delcath Systems stock overvalued right now?
Based on GuruFocus' analysis, Delcath Systems (DCTH) is currently considered Significantly Undervalued. The stock's GF Value™ is $36.67, compared to a current price of $12.23 — trading 66.6% below its estimated fair value. The current EBITDA Margin % is -6.03%. Delcath Systems' overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Delcath Systems (DCTH), the current EBITDA Margin % is -6.03% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Delcath Systems (DCTH) Overvalued in 2026?
Based on GuruFocus' analysis, Delcath Systems stock appears to be undervalued.
The current stock price of $12.23 is trading 66.6% below its estimated GF Value™ of $36.67.
GuruFocus considers Delcath Systems to be Significantly Undervalued.
Key valuation signals for DCTH:
EBITDA Margin %: -6.03%
GF Value™: $36.67 vs. price of $12.23 (66.6% below fair value)
No single metric tells the full story. See the DCTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
70GF Score
Get the complete analysis for DCTH
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DCTH has been successfully added to your 
